Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
Bing Z. Carter(The University of Texas MD Anderson Cancer Center), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Muharrem Müftüoğlu(The University of Texas MD Anderson Cancer Center), Wenjing Tao(Southwest University), Yuki Nishida(Saga University), Edward Ayoub(The University of Texas MD Anderson Cancer Center), Torsten Haferlach(Martin Luther Christian University), Phuong K. Morrow(Cornell University), Lauren B. Ostermann(The University of Texas MD Anderson Cancer Center), Sanam Loghavi(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Steffen Boettcher(University Hospital of Zurich), Po Yee Mak(The University of Texas MD Anderson Cancer Center), Vivian Ruvolo(Hormel (United States)), Paul E. Hughes(Amgen (United States)), Steven M. Kornblau(The University of Texas MD Anderson Cancer Center)
Cited by 33
Related Papers
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951